mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for CD2
Gene summary
Basic gene Info.Gene symbolCD2
Gene nameCD2 molecule
CytomapUCSC genome browser: 1p13.1
Type of geneprotein-coding
DescriptionCD2 antigen (p50), sheep red blood cell receptorLFA-3 receptorT-cell surface antigen CD2T-cell surface antigen T11/Leu-5erythrocyte receptorlymphocyte-function antigen-2rosette receptor
Modification date20141207
dbXrefs MIM : 186990
Ensembl : ENSG00000116824
HPRD : 01750
Vega : OTTHUMG00000022750
ProteinUniProt: P06729
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_CD2
BioGPS: 914
PathwayNCI Pathway Interaction Database: CD2
Pathway Commons: CD2
ContextiHOP: CD2
ligand binding site mutation search in PubMed: CD2
UCL Cancer Institute: CD2
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO:0032760positive regulation of tumor necrosis factor production19109405
GO:0034113heterotypic cell-cell adhesion15345303
GO:1902715positive regulation of interferon-gamma secretion19109405

Ligand binding site mutations for CD2
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for CD2
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for CD2 from PDB

Differential gene expression and gene-gene network for CD2
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of CD2 and the right PPI network was created from samples without mutations in the LBS of CD2. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for CD2
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C0003873Arthritis, Rheumatoid2Biomarker, GeneticVariation
umls:C0027726Nephrotic Syndrome1Biomarker

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for CD2
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of CD2 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of CD2
Multiple alignments for P06729 in multiple species
LBSAA sequence# speciesSpecies
D44QDINLDIPSFQ1Homo sapiens
D44HGITLNIPNFQ1Mus musculus
D44HGINLNIPNFQ1Rattus norvegicus
E128DLKIQERVSKP1Homo sapiens
E128DVRILERVSKP1Mus musculus
E128DLRILEMVSKP1Rattus norvegicus
F87DTYKLFKNGTL1Homo sapiens
F87ETYEVLANGSL1Mus musculus
F87GAFEILANGDL1Rattus norvegicus
N150TCEVMNGTDPE1Homo sapiens
N150TCAVLQGTDFE1Mus musculus
N150TCEVLEGTDVE1Rattus norvegicus
N89YKLFKNGTLKI1Homo sapiens
N89YEVLANGSLKI1Mus musculus
N89FEILANGDLKI1Rattus norvegicus
S131IQERVSKPKIS1Homo sapiens
S131ILERVSKPMIH1Mus musculus
S131ILEMVSKPMIY1Rattus norvegicus
T91LFKNGTLKIKH1Homo sapiens
T91VLANGSLKIKK1Mus musculus
T91ILANGDLKIKN1Rattus norvegicus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas